SynthesisBritish journal of cancer2013
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
Synthesis in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.PloS one · 2016Pooled it
- Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.Haematologica · 2018Trial
- An evolutionary medicine and life history perspective on aging and disease: Trade-offs, hyperfunction, and mismatch.Evolution, medicine, and public health · 2025Review
- mTOR signaling is required for phagocyte free radical production, GLUT1 expression, and control ofmBio · 2024Article
- The microbiota and renal cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts.Journal for immunotherapy of cancer · 2023Article
- Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors.Life (Basel, Switzerland) · 2021Review
- Article
- Article
- Review
- mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack.Haematologica · 2018Article
- Immunomodulation and Disease Tolerance to Staphylococcus aureus.Pathogens (Basel, Switzerland) · 2015Review
- Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors.Biomarker insights · 2015Review
- Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.Medical oncology (Northwood, London, England) · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies. Infections have been reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer patients treated with these agents.
methodsPubmed and oncology conferences' proceedings were searched for studies from January 1966 to June 2012. Studies were limited to phase II and III randomised controlled trials (RCTs) of everolimus or temsirolimus reporting on cancer patients with adequate safety profiles. Summary incidences, relative risks (RRs), and 95% confidence intervals (CIs) were calculated.
resultsA total of 3180 patients were included. The incidence of all-grade and high-grade infections due to mTOR inhibitors was 33.1% (95% CI, 24.5-43.0%) and 5.6% (95% CI, 3.8-8.3%), respectively. Compared with controls, the RR of all-grade and high-grade infections due to mTOR inhibitors was 2.00 (95% CI, 1.76-2.28, P<0.001) and 2.60 (95% CI, 1.54-4.41, P<0.001), respectively. Subgroup analysis found no difference in incidences or risks between everolimus and temsirolimus or between different tumour types (renal cell carcinoma (RCC) vs non-RCC). Infections included respiratory tract (61.7%), genitourinary (29.4%), skin/soft tissue (4.2%), and others (4.9%).
conclusionTreatment with mTOR inhibitors is associated with a significant increase in risk of infections. Close monitoring for any signs of infections is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.